Results 41 to 50 of about 41,270 (209)

Novel BRCA2-Interacting Protein, LIMD1, Is Essential for the Centrosome Localization of BRCA2 in Esophageal Cancer Cell

Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, 2016
Mutation of breast cancer 2, early onset (BRCA2) has been identified as a vital risk factor for esophageal cancer (EC). To date, several proteins have been reported as BRCA2-interacting proteins and are associated with multiple biological processes. This study’s aim was to identify a novel interactive protein of BRCA2 and to explore its functional ...
Hou, Xiaobin, Li, Tinghui, Ren, Zhipeng, Liu, Yang   +3 more
openaire   +3 more sources

BRCA1 and BRCA2 proteins: roles in health and disease. [PDF]

Molecular Pathology, 1998
Between 5% and 10% of all breast cancer is hereditary, with patients having a strong family history of the disease. The remaining 90-95% of cases are classed as sporadic. Within the inherited group, 80-90% of cases are the result of germline mutations affecting two recently identified genes: BRCA1 and BRCA2.
J A, Duncan, J R, Reeves, T G, Cooke
openaire   +2 more sources

Effects of the missense mutations in canine BRCA2 on BRC repeat 3 functions and comparative analyses between canine and human BRC repeat 3. [PDF]

PLoS ONE, 2012
Mammary tumors are the most common tumor type in both human and canine females. Mutations in the breast cancer susceptibility gene, BRCA2, have been found in most cases of inherited human breast cancer.
Yasunaga Yoshikawa, Kazuhiko Ochiai, Masami Morimatsu, Yu Suzuki, Seiichi Wada, Takahiro Taoda, Satomi Iwai, Seishiro Chikazawa, Koichi Orino, Kiyotaka Watanabe   +9 more
doaj   +1 more source

A complete protein truncation test for BRCA1 and BRCA2 [PDF]

European Journal of Human Genetics, 1998
The protein truncation test (PTT) is currently the fastest method in general use for detecting previously unidentified mutations in tumor suppressor genes. Greater than three kilobases of coding sequence can be screened by one PCR reaction, one coupled in vitro transcription/translation reaction, and one lane on an SDS-PAGE gel.
openaire   +2 more sources

Interactions between human BRCA2 protein and the meiosis‐specific recombinase DMC1 [PDF]

The EMBO Journal, 2007
Germline mutations in BRCA2 predispose to hereditary breast cancers. BRCA2 protein regulates recombinational repair by interaction with RAD51 via a series of degenerate BRC repeat motifs encoded by exon 11 (BRCA2(996-2113)), and an unrelated C-terminal domain (BRCA2(3265-3330)). BRCA2 is also required for meiotic recombination. Here, we show that human
Thorslund, T, Esashi, F, West, S
openaire   +2 more sources

Tumor and germline testing with next generation sequencing in epithelial ovarian cancer: a prospective paired comparison using an 18‐gene panel

Molecular Oncology, EarlyView.
Genetic testing in epithelial ovarian cancer includes both germline and tumor‐testing. This approach often duplicates resources. The current prospective study assessed the feasibility of tumor‐first multigene testing by comparing tumor tissue with germline testing of peripheral blood using an 18‐gene NGS panel in 106 patients.
Elisabeth Spenard, Cristina Mitric, Melanie Care, Tracy L. Stockley, Raymond H. Kim, Jeanna McCuaig, Blaise Clarke, Laura Ranich, Clare Sheen, Sarah E. Ferguson, Liat Hogen, Taymaa May, Marcus Q. Bernardini   +12 more
wiley   +1 more source

Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1 [PDF]

Human Molecular Genetics, 2003
Fanconi anaemia (FA) is an autosomal recessive genetic disorder characterized by progressive bone marrow failure, multiple congenital abnormalities, and an increased risk of cancer. FA cells are characterized by chromosomal instability and hypersensitivity to DNA interstrand crosslinking agents.
Hussain, S, Witt, E, Huber, P A J, Medhurst, A L, Ashworth, A, Mathew, C G   +5 more
openaire   +3 more sources

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

PALB2 Functionally Connects the Breast Cancer Susceptibility Proteins BRCA1 and BRCA2 [PDF]

Molecular Cancer Research, 2009
Abstract BRCA1 and BRCA2 are prominently associated with inherited breast and ovarian cancer. The encoded proteins function in DNA damage responses, but no functional link between BRCA1 and BRCA2 has been established. We show here that PALB2 physically and functionally connects BRCA1 and BRCA2 into a DNA damage response network that ...
Fan, Zhang, Qiang, Fan, Keqin, Ren, Paul R, Andreassen   +3 more
openaire   +2 more sources

Does tumorigenesis select

for

or

against

mutations of the DNA repair-associated genes BRCA2 and MRE11?: Considerations from somatic mutations in microsatellite unstable (MSI) gastrointestinal cancers

BMC Genetics, 2006
Background The BRCA2 and MRE11 proteins participate in the repair of double-strand DNA breaks by homologous recombination. Germline BRCA2 mutations predispose to ovarian, breast and pancreatic cancer, while a germline MRE11 mutation is associated with an
Elghalbzouri-Maghrani Elhaam, Brody Jonathan R, van der Heijden Michiel S, Zdzienicka Malgorzata Z, Kern Scott E   +4 more
doaj   +1 more source